University of Wyoming
1174 Snowy Range Road
Laramie, WY 82070
Phone: (307) 766-9925
Fax: (307) 721-2051
Dr. Adamovicz is a doctorate level research microbiologist/immunologist with expertise in bacterial vaccine development. As a retired Army officer his additional specialties/experience include scientific leadership and management, development of biological defense doctrine and tactics, field diagnostic assay development, and the development of vaccines and therapeutic agents for bacterial pathogens such as anthrax, plague and tularemia.
Currently, Dr. Adamovicz is an Assistant Professor in the Veterinary Sciences Department, College of Agriculture at the University of Wyoming. His responsibilities include research, teaching and service with the Wyoming State Veterinary Lab. His laboratory will focus on brucellosis research. In particular, current studies are divided between innate and acquired immunity to B. abortus. We wish to explore the role of dendritic cells in chronic disease and determine if dendritic cells can be targeted to express protective antigens. Our long-term focus is the development of a new brucellosis vaccine for elk and bison. The laboratory currently uses modern molecular techniques including cloning, recombinant gene expression and traditional methodologies such as cell culture systems, microscopy and flow cytometry to achieve our research aims.
Previously, he served as the Principal Scientific Advisor for MRI’s Frederick, Maryland office - a technical services consulting group supporting a variety of government and non-government clients and head of the Center for Biological Safety and Security (CBS2). He was responsible for the scientific aspects of all assigned projects related to laboratory capacity building, biosafety, threat assessment and disease surveillance projects in support of numerous threat reduction and biosecurity programs worldwide. The MRI-Frederick office also provides expert consulting and training services related to national and international laboratories procedures and technology, biosafety and biosecurity issues, and emergency management, CBRN defense, national security policy and intelligence research and analysis.
Other scientific positions include Chief of Bacteriology at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). In this capacity he supervised over 80 scientists in two Institutes, including three different BSL-3 suites and three BSL-2 suites working on vaccine development projects for anthrax, plague, meliodosis, and brucellosis. He simultaneously served as the U.S. Army Task Area Manager for all bacterial vaccine and therapeutics development. In particular he was the product manager for plague vaccine development, transitioning the vaccine product from discovery to advanced development in the Army acquisition program. He was also responsible for development of several analytical assays to measure immune responses to the plague vaccine. These include the quantitative ELISA for the mouse, rabbit and NHP, the competitive ELISA for the mouse and NHP, passive transfer assays and the macrophage cytotoxicity inhibition assay. The macrophage cytotoxicity inhibition assay developed at USAMRIID is the same assay that DVC seeks to scale and validate.
Prior to that he served as the Deputy Bacteriology Division Chief, Department chief and a senior research investigator at USAMRIID. As a biosafety level three (BSL-3) suite supervisor he ran an independent research laboratory studying the innate immune response to bacterial threat agents. He supervised other principal investigators and post-doctoral fellows plus technicians and associated support staff in a multi-disciplinary research.
Dr. Adamovicz has a Ph.D. in Microbiology from the Uniformed Services University of Health Sciences in Bethesda, Maryland, and a B.A. in Biotechnology from the University of Northern Iowa in Cedar Falls, Iowa. He has additional education in product development, GLP/GMP and Army acquisition. Dr. Adamovicz is a member of ABSA and a Registered Biosafety Professional, a member of the American Society for Microbiology (ASM), an ad hoc reviewer for several scientific journals and a grant reviewer for the National Institutes of Health. He has authored or coauthored more than 30 peer-reviewed journal articles and 8 book chapters. He also holds a U.S. patent for an antibody-based therapy for the treatment of plague.
1. S. Welkos, S. Norris, J. Adamovicz. (2008). A modified caspase-3 assay correlates with immunity of nonhuman primates to infection by Yersinia pestis. Clin. Vac. Immunol. 15:1134-37.
2. S.F. Little, W.M. Webster, H. Wilhelm, B. Powell, J. Enama, J.J. Adamovicz. (2008). Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in-vitro based potency assay of plague vaccine in mice. Biologicals. 36:287-95.
3. P.A. Arlen, M. Singleton, J.J. Adamovicz, Y. Ding, A. Davoodi-Semiromi, H. Daniell. (2008). Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun. 76:3640-50.
4. N. Parthasarathy, R. Saksena, P. Kovac, D. DeShazer, S.J. Peacock, V. Wuthiekanun, H.S. Heine, A.M. Friedlander, C.K. Cote, S.L. Welkos, J.J. Adamovicz, S. Bavari, D.M. Waag. (2008). Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis, and Francisella tularensis antibodies. Carbohydrate Res. 343:2783-2788.
5. L.W. Kummer, F. M. Szaba, M. A. Parent, J.J. Adamovicz, J. Hill, L. J. Johnson, S.T. Smiley. (2008). Antibodies and cytokines independently protect against pneumonic plague. Vaccine. 26:6901-7.
6. K. Amemiya, J.L. Meyers, T. Rogers, P.L. Worsham, B. Powell, S.L. Norris, A.M. Krieg, J.J. Adamovicz. (2009). CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine. 27:2220-29
7. H.C. Gelhaus, D.A. Rozak, W.C. Nierman, D. Chen, R.L. Ulrich, J.J. Adamovicz*. (2009). Regulation of the Y. pestis virulence factor LcrV by the quorum sensing molecules N-Octanoyl-Homoserine Lactone and N-(3-oxooctanoyl)-Homoserine Lactone. Microb.Pathog. 46:283-7.
8. S.F. Little, W.M. Webster, H. Wilhelm, D. Fisher, S.L. Norris, B. Powell, J. Enama, J.J. Adamovicz (2010). Quantitiative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice. Vaccine 28:934-9.
9. G.P. Andrews, G. Vernati, R. Ulrich, T.E. Rocke, W.H. Edwards, and J.J. Adamovicz (2010). Identification of In Vivo-induced Conserved Sequences (IVICS) from Yersinia pestis During Experimental Plague Infection in the Rabbit. Vector Borne and Zoonotic Diseases. 10(8):749-56
10. D.A. Rozak, H.C. Gelhaus, M. Smith, M. Zaheh, L. Huzella, D. Waag, J.J. Adamovicz. (2010). Immunostimulatory CpG oligodeoxyribonucleotides differentially protect mice from aerosolized B. pseudomallei 1026b and F. tularensis Schu S4 infections. BMC Journal of Immune Based Therapies and Vaccines. 8:2-5
11. S. Lin, S. Park, J.J. Adamovicz, J. Hill, J.B. Bliska, C.K. Cote, D.S. Perlin, K. Amemiya, S.T. Smiley. (2010). TNF-a and IFN-g contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine. Dec16; 29(2):357-62
12. P. Fellows, J. Adamovicz, J. Hartings, R. Sherwood, W. Mega, T. Brasel, E. Barr, L. Holland, W. Lin, A. Rom, W. Blackwelder, J. Price, S. Morris, D. Snow, M.K. Hart (2011). Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine. Nov16; 28(49):7748-56
13. C.Y. Lindsey, S.F. Little, S. Norris, B. Powell, J.J. Adamovicz*. (In Press). Validation of quantititative ELISA for the measurement of anti-Yersinia pestis F1 and V antibody concentration in non-human primate sera. J. Immuno Assays & Immunochem.
1. Adamovicz, J.J. *and Worsham, P.L. (2011). Chapter 8; Laboratory Animal Models of Plague. Biodefense: Research Methodology and Animal Models. 2nd Ed CRC Press. Boca Raton, FL. Ed. James Swearengen.
2. Adamovicz, J.J.*, Waag, D.M. (2011). Chapter 9; Laboratory Animal Models of Tularemia. Biodefense: Research Methodology and Animal Models. 2nd Ed CRC Press. Boca Raton, FL. Ed. James Swearengen.
1. U.S. 10/987,533 and PCT/US2004/38480 filed 11/12/2004. Awarded 18 May 2010 #7,718,779; Prophylactic, and therapeutic monoclonal antibodies (specific for the virulence (V) antigen of Yersinia pestis). Tran C. Chanh, Gerald P. Andrews, Jeffrey J. Adamovicz and Bradford S. Powell.